Keane told investors he welcomed the chance to assist in the transition of the company, and said he looked forward to focussing on the development of its existing technologies whilst also exploring new growth opportunities.
It comes after the resignation of Mathew Lehman and a decision last month to drop plans to acquire a weight loss drug called orlistat. Before that, in December, Martin Mintchev resigned from his position as chief scientific officer.
In a statement to the market, M Pharmaceuticals’ board told investors: "Brian has the requisite knowledge and capital markets experience to execute M Pharma's technology development plan, raise the necessary capital and explore an acquisition strategy while providing leadership to the management team pending the appointment of a full time CEO".
Keane has more than seventeen years of experience in capital markets, investing and corporate consultancy and has been involved in the restructuring of some 75 different companies.